TGFB1 and neoplasm: This agent can act both as a TGF-β “trap”and as an anti PDL1 agent, resulting, in preclinical studies, in an increased density of CD8+ tumor-infiltrating lymphocytes in murine models and reversion of EMT in human lung cancer cell, as shown in preclinical studies [34].